<DOC>
	<DOC>NCT00731224</DOC>
	<brief_summary>This study will evaluate compliance, tolerability, safety, efficacy and caregiver burden of rivastigmine patch 10 cm² treatment in people with Alzheimer's disease (MMSE 10-26) initiating therapy for the first time with a cholinesterase inhibitor, and in patients who were unresponsive to previous cholinesterase inhibitor treatment in a community setting.</brief_summary>
	<brief_title>Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Probable Alzheimer's disease according to the NINCDSADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) and DSMIV (Diagnostic and Statistical Manual of Mental Disorders) criteria; MMSE score of ≥10 and ≤ 26; Bradycardia (beats per minute less than 50) Body weight less than 40 kg; Hypersensitivity to cholinesterase inhibitors. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Alzheimer's disease, rivastigmine, patch</keyword>
</DOC>